Microsomal transfer protein (MTP), apoCIII and ANGPTL3 inhibitors, and a fibroblast growth factor (FGF21) analogue, have all shown efficacy in treating hypertriglyceridaemia (HTG), with TG reductions of approximately 45% to 80% depending on the clinical setting. This was how Professor Marcello Arca (Sapienza University, Rome, Italy) summarised current data at the end of his wide-ranging review of novel approaches to TG lowering.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
